Compare URGN & DCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URGN | DCO |
|---|---|---|
| Founded | 2004 | 1849 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2016 | 1995 |
| Metric | URGN | DCO |
|---|---|---|
| Price | $47.11 | $197.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $29.29 | ★ $153.60 |
| AVG Volume (30 Days) | ★ 795.1K | 267.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.95 |
| Revenue | $1,128,000.00 | ★ $824,730,000.00 |
| Revenue This Year | $129.09 | $7.40 |
| Revenue Next Year | $70.96 | $8.59 |
| P/E Ratio | ★ N/A | $100.56 |
| Revenue Growth | N/A | ★ 4.85 |
| 52 Week Low | $15.86 | $84.76 |
| 52 Week High | $48.19 | $210.39 |
| Indicator | URGN | DCO |
|---|---|---|
| Relative Strength Index (RSI) | 67.57 | 63.99 |
| Support Level | $18.23 | $165.13 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 2.39 | 8.58 |
| MACD | 0.35 | 1.68 |
| Stochastic Oscillator | 86.58 | 71.82 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers and manufactures various sizes of complex contoured aerostructure components and assemblies and supplies composite and metal bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets including A&D and Industrial end-use markets. It generates maximum of its revenue from the Electronic Systems.